The Trip Report goes through the latest psychedelic news from February 2022. Highlights include Novamind’s ketamine-assisted therapy, Fluence’s $3 million seed round, and reporting on the 12-month Johns Hopkins depression follow-up study.
Fluence is one of the largest training companies offering education for (future) psychedelic therapists, with a focus on ketamine.
Novamind has bold plans for building out a psychedelic ecosystem. One that spans from ketamine-assisted psychotherapy and psilocybin retreats to novel clinical trials.
Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.
People FeaturedReid Robison
Reid Robison is CMO at Novamind.
Article AuthorZach Heigney
Zach Heigney is the excellent writer behind the insightful The Trip Report publication.
Paper FeaturedEfficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
This 12-month follow-up study (n=24) assessed the efficacy and safety of psilocybin in depressed participants from a previous trial. A durable antidepressant effect was observed with treatment response (⩾50% reduction in GRID-HAMD score from baseline, Cohen d = 2.4) and rate of remission at 75% and 58%, respectively, at 12 months. No serious adverse events related to psilocybin were observed.